FDA Warns Against Bystolic For Heart Patients

By Liz McKenzie

Law360, New York (January 07, 2010, 2:24 PM ET) -- Researchers at the U.S. Food and Drug Administration are urging the agency not to approve Forest Laboratories Inc.’s hypertension drug Bystolic for use with heart failure patients.

The agency’s advisory committee, which is set to discuss Bystolic in a meeting Monday, released background memos on Thursday cautioning against approving the drug for use in patients with heart failure.

“The totality of the evidence is not convincing to support a claim for treatment of heart failure,” FDA medical reviewer Shone Pendse said in documents prepared for the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles